Date of Award


Document Type


Degree Name

Master of Physician Assistant Studies


Physician Assistant Education

First Advisor

Rahnea Sunseri


Since the beginning of the United States AIDS epidemic in the early 1980s, the medical community has overcome significant challenges in the diagnosis and treatment of Human Immunodeficiency Virus (HIV) infections. Many advancements in suppressing HIV viral loads and maintaining healthy immune system function in HIV positive patients have been achieved with antiretroviral therapy (ART). Moreover, these drugs have been shown to be effective for preventing HIV infections. Once-daily Truvada (emtricitabine/tenofovir disoproxil fumarate) has been approved by the FDA for this purpose. The availability of this preventive therapy, commonly known as preexposure prophylaxis (PrEP), necessitates educating at-risk patient populations about its prophylactic benefits. In order to select appropriate candidates for PrEP prophylaxis, its efficacy in different at-risk populations needs to be determined. This investigation examines disparities in PrEP’s efficacy among at-risk groups and proposes explanations that may guide the medical provider in offering PrEP therapy to patients who could benefit. Additionally, current clinical trials and studies with alternative PrEP options will be explored.

Jones_Presentation Slides.pptx (25834 kB)
Click here to download Presentation Slides

Jones_Presentation Slides.pptx (25834 kB)
Click here to download Presentation Slides



To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.